Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital Yun-Lin Branch, Yun-Lin 640, Taiwan.
Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei 100, Taiwan.
J Clin Endocrinol Metab. 2023 Dec 21;109(1):92-99. doi: 10.1210/clinem/dgad448.
Atrial fibrillation (AF) has been linked to increased hyperthyroidism risk, but contributing factors are unclear.
We aimed to investigate whether AF could predict hyperthyroidism and related risk factors.
This retrospective cohort study was conducted in a tertiary medical institution and included patients aged 18 years or older with AF but without hyperthyroidism at diagnosis. The endpoint was defined as newly diagnosed hyperthyroidism during the follow-up period.
The study cohort included 8552 participants. Patients who developed new hyperthyroidism were younger and the proportion of females was higher. They had fewer comorbidities, including diabetes (26% vs 29%, P = .121), hypertension (51% vs 58%, P < .001), coronary artery disease (17% vs 25%, P < .001), stroke (16% vs 22%, P < .001), and end-stage renal disease (ESRD) (6% vs 10%, P = .001). The CHADS2 score was lower in patients with hyperthyroidism (1.74 vs 2.05, P = .031), but there was no statistically significant difference in the CHA2DS2-VASc and HAS-BLED score. Cox regression analysis identified younger age, female gender, history of congestive heart failure, hypertension, diabetes, non-ESRD status, and lower CHADS2 score but not CHA2DS2-VASc as independent predictors of incident hyperthyroidism during follow-up. We also propose a novel, simple risk stratification score (SAD HEC2 score) with excellent predictive power for incident hyperthyroidism during follow-up.
Our results provide insight into clinical risk factors for the development of hyperthyroidism in AF patients, as identified by the novel SAD HEC2 score. AF appears to be a common precursor of hyperthyroidism.
心房颤动(AF)与甲状腺功能亢进症风险增加有关,但具体的致病因素尚不清楚。
本研究旨在探讨 AF 是否可以预测甲状腺功能亢进症及其相关危险因素。
本回顾性队列研究在一家三级医疗机构中进行,纳入了年龄在 18 岁及以上且在诊断时无甲状腺功能亢进症但患有 AF 的患者。随访期间新诊断为甲状腺功能亢进症作为终点事件。
研究队列共纳入 8552 名参与者。新发甲状腺功能亢进症患者的年龄更小,女性比例更高。与未发生甲状腺功能亢进症的患者相比,他们合并症较少,包括糖尿病(26%比 29%,P =.121)、高血压(51%比 58%,P <.001)、冠心病(17%比 25%,P <.001)、卒中和(16%比 22%,P <.001)、终末期肾病(ESRD)(6%比 10%,P =.001)。甲状腺功能亢进症患者的 CHADS2 评分较低(1.74 比 2.05,P =.031),但 CHA2DS2-VASc 和 HAS-BLED 评分无显著差异。Cox 回归分析确定年龄较小、女性、充血性心力衰竭、高血压、糖尿病、非 ESRD 状态和较低的 CHADS2 评分,但不是 CHA2DS2-VASc 评分是随访期间发生甲状腺功能亢进症的独立预测因素。我们还提出了一种新的、简单的风险分层评分(SAD HEC2 评分),该评分对随访期间甲状腺功能亢进症的发生具有良好的预测能力。
我们的研究结果为 AF 患者甲状腺功能亢进症发展的临床危险因素提供了新的见解,SAD HEC2 评分可以预测甲状腺功能亢进症的发生。AF 似乎是甲状腺功能亢进症的常见前兆。